Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Quiet period right now can't say much at all. Perhaps they will fill the void with a company not in the space they currently are/were in. The name change is an indication of sorts.
hi
parrishilton, you where right about
bmsn, they went down hill in the worst
way back then. Im glad in a better
position now. thanks again for your
warnings.
YUP....It also shows up on BARCHARTS. Ihub has two separate entries. Gotta admit it is a little befuddling(sp). glta
There does
seem to be some confusion ...2 ENTI boards 1 ETNI board all with a lot of server error's...
Must be trying to merge them ?
I found it on IHub.
There is no ETNI board,
Ron Rooster has set up a new board at ETNI for any followers here. At least until ticker change. In contact w IHub admin
you may or may not be right
you might be right or wrong ?
hard to say someone must know
why does this happen ?
sure looks great new name
Mods - please update the correct ticker.
02/13/2018 10:46:29 02/14/2018 00:00:00 ENTB ETNI Entest BioMedical Inc. Common Stock Entest Group, Inc. Common Stock
$ETNI
ETNI is the new ticker.
Shows as encounter technologies....
ENTB symbol changed to ENTI effective February 14, 2018
Name change from Entest Biomedical Inc. to Entest Group Inc.
http://otce.finra.org/DLSymbolNameChanges
SORRY.CORRECTION.SHOULD BE ETNI
NEW SYMBOL STARTING FEB 14.ENTI
Could u post link.thanks.
The Entest website is pretty much the Zander site now, recent changes prior to shares coming available
You may be onto something.My thought is that they have an currently private company in mind and the announcement will be made on or just before the effective date of ZANDER divvy shares.ie company such as ANIVIVE? GLTU.
Ron, perhaps veterinary parasitology gets added to the group that is coming when this becomes Entest Group on 2/12/18. Mentioned somewhere along the line and one or more of the vets on the board has extensive experience in that domain. Hopefully the Entest Group gets it going SOON..All IMO.
I was just doing a little venting , not going anywhere, actually love this stock and it's opportunity.
It’s coming, of u check Edgar, approvals r given every day, just going thru backlog
LOL , I know down 54% and been here over 3 years , I think I deserve to be anxious , added more last year under 20 and tried to buy more a couple times and couldn't get filled. Not paying 30+ for more
Patience, grasshopper
Beginning to wonder if it's going to happen
Probably around 144,000 ZANDER shares.if they list at $1.00 (as per private placement) works out to $.0576 per ENTB share purchased.no idea as what they paid for ENTB shares.gltu.
Somebody will be getting a lot of Zander shares
Life secience journeys founded 10/17/17. Wonder how much of this one koos owns, his name isn't on it but who knows with him.
just out..13g statement of ownership.Seems funny that someone would buy just over 5% so that they would have to register with sec.good news is that outstanding shares are still around 49.2 million.GLTA.UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
ENTEST BIOMEDICAL, INC
(Name of Issuer)
Common Stock, par value $0.001
(Title of Class of Securities)
29383T102
(CUSIP Number)
January 26, 2018
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 29383T102
1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Life Sciences Journeys, Inc. (82-3143794)
CITIZENSHIP OR PLACE OF ORGANIZATION
Wyoming, USA
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5.
SOLE VOTING POWER
2,500,000
6.
SHARED VOTING POWER
2,500,000
7.
SOLE DISPOSITIVE POWER
2,500,000
8.
SHARED DISPOSITIVE POWER
2,500,000
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,500,000
10.
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ¨
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.08%
12.
TYPE OF REPORTING PERSON (see instructions) CO
Item 1.
(a)
Name of Issuer
Entest BioMedical Inc.
(b)
Address of Issuer’s Principal Executive Offices
4700 Spring St, Suite 304
La Mesa, CA
91942
Item 2. (a)
Name of Person Filing
Life Sciences Journeys, Inc
(b)
Address of the Principal Office or, if none, residence
109 East 17 th Street, Suite 25
Cheyenne, WY
82001
(c)
Citizenship
USA
(d)
Title of Class of Securities
Common stock, par value $0.001
(e)
CUSIP Number
29383T102
(k)
A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: N/A
Item 4. Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a)
Amount beneficially owned: 2,500,000
(b)
Percent of class: 5.08%
(c)
Number of shares as to which the person has:
(i)
Sole power to vote or to direct the vote: 2,500,000
(ii)
Shared power to vote or to direct the vote: 2,500,000
(iii)
Sole power to dispose or to direct the disposition of: 2,500,000
(iv)
Shared power to dispose or to direct the disposition of: 2,500,000
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨ .
Instruction . Dissolution of a group requires a response to this item.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
N/A
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
N/A
Item 8. Identification and Classification of Members of the Group.
N/A
Item 9. Notice of Dissolution of Group.
N/A
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: January 30, 2018 Life Sciences Journeys
By: /s/ Ivan DiTmars
Name: Ivan DiTmars
Just for fun..what thoughts as to Entest Group's next possible acquisition? I would venture that it does not have to be on the same field as all other Koos companies.
$ENTB-Entest Bio Medical changed it's name to Entest Group. Could mean the structure is changing as well with Sub Zander set to Spin Off
New Zander Shares may be paid to ENTB Shareholders. Are you prepared?
https://www.otcmarkets.com/stock/ENTB/quote …
https://www.zandertherapeutics.com/
Some progress..S-1A out today. Hopefully we get the Effective date soon. Effective date will be the record date for our dividend in Zander shares.GLTA
Hope it works out for you.gl.
Ron thanks for the info, after the RS I am down to 30k shares. I lost 25k in BMSN but ill ride what I have here out and how to recover some portion of my losses.
It appears you have held ENTB stocks since mid 2014.Myself as well.You expressed the need for some real news, so here it is in case you missed it. 1) you are receiving an dividend of approx. 6 % of your ENTB shares in Zander shares which should be worth at least $1.00 share based on the recent sale of 900,000 shares.2) in order for the ENTB shares not to be worthless after the issuance of the dividend, ENTB will become ENTB GROUP and since it has little debt and only 50 m o/s, will be able to acquire some business(es).IMO your patience will pay off in the near future.GLTU.
LOL Joker, are you really expecting a reasonable answer from Koos? Hell did you see that fool list himself as a note holder for $100.00. Been here so long I cant remember anymore, hoping to wake up one day and have some real news and not more Koos fluff.
I am sure we will get more communication as we get closer.Probably looking at uplisting on otc as well.Not an debt issue.Entest may end up being an holding company.Time will tell.imo
Very interesting indeed.The new name would enable Entest to participate in ANY market.Perhaps blockchain applications,animal cbd etc.etc. Definitely going to hang on to my ENTB and wait for the ride.GLTU
Entest Biomedical to Entest Group...Why the name change? No longer totally biomedical? What's going to be in the group? Need an explanation. Would like to hear.
A. Change in management / shareholding structure Change company name
B. Change of business direction / business activities/ acquisition(s)
C. Change of image / Rebranding
D. Change company’s name for shelf company
E. Debt avoidance
Not a fan of another stock going public if that's the plan. A small % dividend in the form of more ENTB shares sure..but that's more dilution too.
A. RGBP
B. RGBPP
C. BMSN
D. ENTB
E. ZAND?
Interesting.
"Effective February 12, 2018 the name of the Company shall be Entest Group, Inc."
Dividend shares and then Zander goes public?
$ENTB
Current Report Filing (8-k)
Date : 01/11/2018 @ 7:13AM
Source : Edgar (US Regulatory)
Stock : Entest Biomedical Inc. (PC) (ENTB)
Quote : 0.0378 0.0 (0.00%) @ 7:56AM
Current Report Filing (8-k)
Print
Alert
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 10, 2018
Commission File Number 333-154989
ENTEST BIOMEDICAL, INC.
(Exact Name of Company as Specified in Charter)
Nevada 26-3431263
(State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.)
4700 Spring Street, Suite 304, La Mesa California 91942
(Address of principal executive offices) (Zip Code)
619-702-1404
(Company’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
? Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 5.03 Amendment of Articles of Incorporation
On January 10, 2018 Entest Biomedical, Inc. ( the “Company”) filed a Certificate of Amendment with the Nevada Secretary of State authorizing a change to the Company’s Articles of Incorporation.
The change is as follows:
Effective February 12, 2018 the name of the Company shall be Entest Group, Inc.
Item 9.01 Exhibits .
Exhibit No. Description of Exhibit
3(i) TEXT OF CERTIFICATE OF AMENDMENT.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ENTEST BIOMEDICAL, INC.
Dated: January 10, 2018 By: /s/ David Koos
David Koos
Chief Executive Officer
Wonder home many companies Koos owns these days? Blackbriar Partners is controlled by David R. Koos, the Company’s sole officer and director
This will come in handy in the near future. Check daily
hint, hint
https://www.sec.gov/cgi-bin/browse-edgar?action=getcurrent&type=EFFECT
Happy New Year's fellow longs. It's been awfully quiet here and at RGBP. We know they left off with news of their continued progress, so the assumption is that positive developments continue in 2018. Each testing step is iterative and leads to more and more concrete evidence that you have a cancer and/or autoimmune busting product. Which leads to funding, partnerships, buyouts. We have been told they are in the zone. Patiently waiting. IMO. GL.
Quarterly report out - buying volume.
$ENTB
Followers
|
376
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
38376
|
Created
|
08/14/09
|
Type
|
Free
|
Moderators |
Regen BioPharma Issues End of Fiscal Year Shareholder Letter
PR Newswire PR NewswireSeptember 19, 2017
SAN DIEGO, September 19, 2017 /PRNewswire/ --
Regen BioPharma Inc. (RGBP) and (RGBPP) President Dr. Harry Lander issued the following fiscal year end shareholder letter:
As the end of Regen's fiscal year 2017 approaches on September 30th, I would like to summarize our progress during the past twelve months and look to the future.
The Marketplace:
Our decision to focus on small molecules to activate and inhibit our primary target of interest, NR2F6, seems prescient. The M&A market indicates that the autoimmunity and immuno-oncology fields are even hotter at the end of the year than they were at the beginning. Although there have been many transactions over the past twelve months, two very recent deals further support this assertion: the $2.3 billion acquisition of IFM Therapeutics, Inc. by Bristol Myers Squibb (which I commented on previously (http://www.prnewswire.com/news-releases/regen-biopharma-inc-addresses-potential-impact-of-recent-bristol-myers-squibb-23-billion-acquisition-of-ifm-therapeutics-639392183.html), and the $11.9 billion acquisition of Kite Pharmaceuticals by Gilead (http://www.gilead.com/news/press-releases/2017/8/gilead-sciences-to-acquire-kite-pharma-for-119-billion).
A Look Back at our Success:
The scientific program focusing on identifying and optimizing small molecule compounds that activate or inhibit NR2F6 and directly inhibit or activate the immune system, respectively, is proceeding well. To our great excitement, we believe we are only three or four months away from having an optimized activator in hand, which we can then test in several animal models of autoimmunity. Similarly, we also expect to have an optimized inhibitor a few months afterward (in calendar Q1 of 2018), which we can then test it in several animal models of cancer.
Plans for the Immediate Future:
We continue to have discussions with multiple big pharma companies. To create the most value for our shareholders, we have elected to continue to develop the NR2F6 program in-house prior to entering into any potential partnerships. The more mature the products, the greater their valuation in the marketplace.
We are now in the process of identifying the major indications on which we will focus our efficacy studies. Obviously, the market size of an indication is important, but equally or even more important is the likelihood of success. Therefore, although we already have a preferred list of indications, we will test these compounds for efficacy in many models of autoimmunity and cancer. Our goal in 2018 is to develop both an activator and inhibitor of NR2F6 that is effective and not toxic in animal models. At that point, we will begin experiments and process manufacturing, which will enable us to apply for testing these compounds in humans.
The drug development process is slow and steady. However, we have had no scientific setbacks, and the small molecule drugs that we are developing are performing exactly as we had hoped they would. This is not usually the case in science and we remain laser-focused on achieving the scientific goals we have set out to achieve. Thus far, we have met each and every scientific target, and we believe that our planned scientific efforts in 2018 will greatly increase the likelihood of striking strategic partnerships with one or more large pharmaceutical companies in the near future.
With warm regards,
Harry Lander
President and Chief Scientific Officer
http://www.barchart.com/headlines/story/8402740/entest-biomedical-inc-in-discussions-to-acquire-nanotechnology-delivery-system-for-cancer-therapy
| Brian Devine, Chairman Business Advisory Board Brian is the former Chairman, CEO, and President of PETCO, where he oversaw the company’s expansion from $80 million to approximately $5 billion in sales. He became Chairman Emeritus at Petco Holdings, Inc. in 2016. Prior to that, he held leadership roles at Toys R Us, including Senior Vice President, Director of Stores for the U.S and Canada. Brian served as a Director at National Retail Federation Inc., Retail Industry Leaders Association, Students in Free Enterprise, Georgetown University Board of Regents, Georgetown University College Board of Advisors, San Diego International Sports Council, and the San Diego Padres. He also served as Director, Chairman of Real Estate Committee, Member of Executive Committee and Member of Nominating Committee at Wild Oats Market prior to it being sold to Whole Foods. He currently is on the Board of Directors of the Ron Fowler School of Business at San Diego State University, the San Diego Sports Alliance, the San Diego Hall of Champions, and on private company boards. |
http://www.zandertherapeutics.com
?Zander Therapeutics is a biotechnology company focused on veterinary therapies that enlist the animals’ own immune system. Zander’s main areas of interest include: autoimmune disorders such as arthritis, immunotherapies for cancer treatment in canines and bone marrow suppression therapy for animals treated with chemotherapy and radiation therapy. ? | |
??Learn more about bone marrow and aplastic anemia therapy as well as small molecule targeting cancer stem cell genes.
Address: Zander Therapeutics, Inc. 4700 Spring Street, Suite 304 La Mesa, CA 91942 U.S.A. ?venturebridge@gmail.com Telephone: (619) 702-1404 Fax: (619) 330-2328 |
| David R. Koos, PhD, DBA Chairman and Chief Executive Officer David Koos is the Founder, Chairman & CEO of Entest BioMedical Inc. Dr. Koos has over 32 years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored or co-authored several peer reviewed journal articles primarily on biotechnology related subjects. |
| ?Harry Lander, PhD, MBA President and Chief Scientific Officer Harry Lander has over 20 years of professional scientific, business and financial management experience related to biomedical research. He has a deep knowledge of operations and research administration. Dr. Lander has a team-oriented management style founded on outstanding communication and interpersonal skills. Highly effective at strategic planning, problem solving and operational excellence. Dr. Lander has extensive relationships with large and small biotechnology / pharmacology companies and entities that Regen BioPharma expects to leverage for company growth. Formerly he has served as Research Chief / Administration for Sidra Medical and Research Center (Doha, Qatar), Assistant Provost for Weill Cornell Medical College (Cornell University), along with serving as Assistant Dean for Research Administration at Weill Cornell Medical College (Cornell University). |
| ?Todd S. Caven Chief Financial Officer Todd S. Caven is an accomplished executive with 30 years of experience in corporate finance, taxation, mergers & acquisitions, corporate valuations and financing activities for various types of transactions. In March of 2009, Mr. Caven co-founded Saguaro Capital Partners, an Arizona based firm that raises growth capital for medical device, pharmacology and technology based companies throughout the western United States. In 2003, Mr. Caven founded Rock Ridge Enterprises, a Minnesota-based boutique Private Equity firm that focuses on the acquisition of manufacturing, distribution, construction and business services firms in the upper Midwest. Prior to founding Rock Ridge Enterprises, he served as the CFO of Atterro Human Capital Group (formerly Pro Staff), a $500 million privately held firm in the Staffing and Recruiting industry. Prior to Atterro, Todd held senior-level finance and marketing positions at Nordic Track and the Carlson Companies, both in Minneapolis, Minnesota. He started his career in corporate finance at Amoco Corporation in Chicago, Illinois (now British Petroleum). Todd earned a Bachelors degree in Accounting from the Tippie College of Business at the University of Iowa, and he received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University. |
| Thomas Donnelly, DVM Senior Veterinary Advisor ? Tom is a board-certified specialist in the field of laboratory animal medicine. He is also Adjunct Associate Professor at Tufts University Cummings School of Veterinary Medicine and Professor (teaching & research) at Ecole Nationale Veterinaire d’Alfort. He provides regulatory guidance, research advice, medical attention and welfare supervision to researchers using animals in scientific investigation and testing. Tom is a board-certified specialist in the field of exotic mammals, and sees primary care and referred patients. His work links the understanding of animal diseases and their complexities with the development of novel therapies for humans and animals. |
| Linda L. Black, DVM, PhD Senior Veterinary Advisor Linda is a leading researcher, published author and currently COO and Vice President of Clinical Science for Medicus Biosciences, a biotech company focused on drug delivery for ophthalmology, advanced wound healing, osteoarthritis, and regenerative medicine applications for pets and people. She has extensive experience in veterinary stem cell research and commercialization. She holds a PhD in Molecular and Cell Biology from The Wistar Institute at University of Pennsylvania School of Medicine, a DVM from University of Wisconsin School of Veterinary Medicine and attended undergraduate training at the University of California at Davis. She completed her post doctoral fellowship at GlaxoSmithKline. |
| ?Thomas Ichim, PhD Senior Research Consultant Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. He spent over seven years as President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Subsequent to the acquisition of Medistem by Intrexon, in a deal worth $26 million, Dr. Ichim was brought on to the parent company in its cell engineering unit as Vice President of Cellular Therapy. |
| ?Debbie Dorsee Director of Business Development The Dorsee Company, founded by Debbie Dorsee, is a leader in public relations for businesses and individuals. With an integrated focus on community relations, marketing, fundraising/capital raising, and business development, The Dorsee Company offers a unique promotional approach that opens doors, forges partnerships, and drives results. ? Debbie Dorsee, a San Diego native, founded The Dorsee Company in 2003. Drawing from her life’s fabric of political campaigns, social events and promotional fundraising, she uses her behind-the-scenes knowledge and community contacts to promote public awareness and drive business results. Debbie was the recipient of the San Diego North Chamber of Commerce’s Volunteer of the Year honor and was named one of San Diego Metropolitan Magazine’s Metro Movers to Watch |
Jonathan Baell, PhD
Scientific Advisory Board
Dr. Baell is a professor or Medicinal Chemist at Monash University (Australia) whose research is focused on the discovery of new medicines for treating diseases with an unmet medical need. A proven record of undertaking original research with a total of 120 publications and patents. He is published in top-ranked journals in the field (e.g. 12 in Journal of Medicinal Chemistry, Nature Chemical Biology,Nature). He has 40 granted patents listed in www.lens.org.
He has won a national award for my discovery of a new class of potential multiple sclerosis therapeutics. Additionally he has achieved successful outcomes in a diverse array of drug discovery arenas, from rational design of peptidomimetics to heterocyclic drug discovery.
For the period 2012-16, Dr. Baell is Chief InvestIgator on competitive grants that currently are totalling $4.73M. In addition, he has been awarded a prestigious NHMRC Senior Research Fellowship for the period 2012-2016. In 2011 and elected as the Australian representative to the Board of Directors for the Inaugural International Chemical Biology Society and appointed Chair of Membership.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |